Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BCRX with free AI briefings, catalyst countdowns, and dilution alerts.

BCRX · BIOCRYST PHARMACEUTICALS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$375M Cash on Hand
CF+ Cash Runway
Follow BCRX by email Get an email when BCRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BCRX, unsubscribe in one click. Privacy

📣 What BCRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Peramivir
FDA approved Dec 2014 · Rapivab
Influenza Phase 3 · NCT01224795 Withdrawn
Berotralstat
FDA approved Dec 2020 · Orladeyo
Hereditary Angioedema Phase 3 · NCT05453968 Active not recruiting
Oseltamivir Influenza Phase 3 · NCT02369159 Completed
Avoralstat Hereditary Angioedema Phase 3 · NCT02670720 Terminated
BCX4161 Hereditary Angioedema Phase 2/3 · NCT02303626 Completed
BCX7353 Hereditary Angioedema Phase 2/3 · NCT03472040 Completed
Forodesine Hydrochloride Leukemia, Lymphocytic, Chronic Phase 2 · NCT00289549 Completed
Ulodesine Gout Phase 2 · NCT01265264 Completed
Forodesine Cutaneous T-cell Lymphoma (CTCL), Phase 2 · NCT00501735 Completed
Pelecopan (BCX9930) Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2 · NCT05116787 Terminated
Galidesivir (BCX4430) Marburg Virus Disease Phase 1 · NCT03800173 Completed
BCX7353 and probes Hereditary Angioedema Phase 1 · NCT02819102 Completed
Rosuvastatin Hereditary Angioedema Phase 1 · NCT03136237 Completed
BCX17725 Netherton Syndrome Phase 1 · NCT06539507 Active not recruiting
BCX10013 Paroxysmal Nocturnal Hemoglobinuria Phase 1 · NCT06100900 Completed

Also used in these trials (approved or third-party drugs, not BCRX's own candidates): Ravulizumab, Eculizumab, Digoxin, Cyclosporine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BCRX holds $375M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BCRX files for a raise →

👥 Who Owns BCRX

Insiders 1.6% Other 5%+ holders 5.6% Institutions (425 holders) 92.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Deerfield Mgmt, L.P. 5%+ holder (13G) 14,341,000 5.57% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 12,961,172 5.04% 2026-03-31
Jon P Stonehouse
Director · +33,540 options
Insider 1,420,419 0.55% 2026-08-31
Charles K Gayer
President and CCO · +1.00M options
Insider 952,583 0.37% 2025-12-19
Alane P Barnes
Chief Legal Officer · +255,050 options
Insider 400,703 0.16% 2026-05-13
Babar Ghias
Chief Financial Officer · +355,050 options
Insider 268,700 0.10% 2025-12-17
Ronald Dullinger
Chief Commercial Officer
Insider 258,372 0.10% 2026-01-01
Sandeep Menon
Chief R&D Officer · +441,350 options
Insider 205,150 0.08% 2026-04-06
Vincent Milano
Director · +33,540 options
Insider 109,642 0.04% 2026-08-31
Steven K Galson
Director · +33,540 options
Insider 86,165 0.03% 2026-06-11
Theresa Heggie
Director · +33,540 options
Insider 80,646 0.03% 2026-06-11
Alan G Levin
Director · +33,540 options
Insider 79,565 0.03% 2026-06-11

Share count 257,299,269 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-09-12 — NDA -3.4% -2% -1.4%

Browse all historical PDUFA outcomes →

Get the full BCRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.